Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

Onco-Innovations Limited has announced promising results from its licensed technology of PNKP inhibitors, which enhance the ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Onco-Innovations’ licensed technology demonstrates promise to enhance chemotherapy effectiveness by overcoming cancer cell resistance: Vancouver, BC Saturday, February 1, 2025, ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Specifically, the novel Trop-2-directed antibody and topoisomerase inhibitor conjugate is indicated for those who have ...

On January 17, 2025, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk a Trop-2-directed antibody and topoisomerase inhibitor conjugate ... factor receptor 2 (HER2)-negative ...

The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 ...

The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate ... HER2-low or HER2-ultralow metastatic breast cancer who disease had progressed on endocrine therapy were randomly ...